Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Asset Writedowns and Impairment: 2009-2015

Historic Asset Writedowns and Impairment for Ligand Pharmaceuticals (LGND) over the last 7 years, with Dec 2015 value amounting to $1.3 million.

  • Ligand Pharmaceuticals' Asset Writedowns and Impairment rose 2103.67% to $2.4 million in Q1 2015 from the same period last year, while for Mar 2015 it was $5.6 million, marking a year-over-year increase of 812.23%. This contributed to the annual value of $1.3 million for FY2015, which is 58.93% down from last year.
  • According to the latest figures from FY2015, Ligand Pharmaceuticals' Asset Writedowns and Impairment is $1.3 million, which was down 58.93% from $3.2 million recorded in FY2014.
  • Over the past 5 years, Ligand Pharmaceuticals' Asset Writedowns and Impairment peaked at $3.2 million during FY2014, and registered a low of -$456,000 during FY2011.
  • In the last 3 years, Ligand Pharmaceuticals' Asset Writedowns and Impairment had a median value of $1.3 million in 2015 and averaged $1.6 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Asset Writedowns and Impairment tumbled by 108.60% in 2011, and later spiked by 851.91% in 2014.
  • Yearly analysis of 5 years shows Ligand Pharmaceuticals' Asset Writedowns and Impairment stood at -$456,000 in 2011, then surged by 412.72% to $1.4 million in 2012, then crashed by 76.09% to $341,000 in 2013, then spiked by 851.91% to $3.2 million in 2014, then crashed by 58.93% to $1.3 million in 2015.